A complex coacervate system is formed by mixing a specially synthesized polycationic polymer (such as PEAD or PELD) with a polyanion like heparin or heparan sulfate. This system features a controlled molecular weight and low polydispersity achieved through precise polymerization, deprotection, and conjugation steps. It incorporates modifiable functional groups, including amine and carboxyl groups, that enable strong binding interactions with a diverse range of biomolecules such as cytokines, interferons, chemokines, peptides, and proteins. With a loading efficiency of approximately 68%, the platform ensures sustained, localized release when injected or embedded in hydrogels for targeted therapeutic applications.
Description
The technology is differentiated by its versatile design and extensive validation in both in vitro and in vivo models. Its customizable chemistry allows for the delivery of nearly 400 biomolecules, significantly reducing systemic exposure compared to conventional methods. Furthermore, its proven efficacy in robust preclinical tests for applications in cancer immunotherapy and myocardial infarction treatment showcases its potential for clinical translation. This level of precision and wide-ranging adaptability sets it apart as a next-generation solution for controlled, targeted biomolecule delivery.
Applications
- Cancer immunotherapy delivery
- Myocardial infarction treatment
- Controlled protein release system
Advantages
- Enables controlled, localized delivery to reduce systemic side effects.
- Provides high loading efficiency and sustained release of therapeutic proteins.
- Offers versatile binding to a broad spectrum of biomolecules, including cytokines, interferons, and peptides.
- Allows customizable polymer structures for tailored delivery profiles through modifiable functional groups.
- Demonstrates improved therapeutic outcomes in both cancer treatment and myocardial infarction therapy.
IP Status
https://patents.google.com/patent/US11779647B2
